Los Angeles Capital Management’s Harmony Biosciences HRMY Stock Holding History

Los Angeles Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Sell	58,425 -107,773	-65%	-$3.4M	0.01%	580
2026 Q1	$4.66M	Buy	166,198 +99,647	+150%	+$3.27M	0.02%	346
2025 Q4	$1.92M	Sell	66,551 -808	-1%	-$26.6K	0.01%	454
2025 Q3	$1.86M	Buy	67,359 +25,933	+63%	+$893K	0.01%	526
2025 Q2	$1.31M	Buy	41,426 +1,524	+4%	+$49K	﹤0.01%	573
2025 Q1	$1.32M	Buy	39,902 +14,552	+57%	+$522K	0.01%	488
2024 Q4	$872K	Hold	25,350	–	–	﹤0.01%	662
2024 Q3	$1.01M	Buy	25,350 +126	+0.5%	+$4.43K	﹤0.01%	650
2024 Q2	$761K	Hold	25,224	–	–	﹤0.01%	741
2024 Q1	$847K	Buy	25,224 +1,076	+4%	+$34.5K	﹤0.01%	741
2023 Q4	$780K	Buy	24,148 +16,555	+218%	+$462K	﹤0.01%	752
2023 Q3	$249K	Sell	7,593 -14,093	-65%	-$489K	﹤0.01%	1012
2023 Q2	$763K	Buy	+21,686	New	+$749K	﹤0.01%	725
2023 Q1	–	Sell	-5,312	Closed	-$293K	–	1225
2022 Q4	$293K	Buy	+5,312	New	+$292K	﹤0.01%	1043

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's HRMY Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Harmony Biosciences (HRMY) stake by 65% in Q2 2026, selling an estimated $3.4M and leaving 58,425 shares worth $2.13M. The position accounts for 0.01% of the portfolio, ranked #580.

Los Angeles Capital Management first reported a position in HRMY in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.66M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Los Angeles Capital Management held 58,425 shares of Harmony Biosciences worth $2.13M as of Q2 2026.
Los Angeles Capital Management sold 107,773 Harmony Biosciences shares in Q2 2026, an estimated $3.4M.
Harmony Biosciences made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #580 holding.
Los Angeles Capital Management first reported a position in Harmony Biosciences in Q4 2022 and has held it in 14 quarters since.
Los Angeles Capital Management's Harmony Biosciences position peaked at $4.66M in Q1 2026.
327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.